OnCo

Create your OnCo account

One account keeps your watchlist, saved views and cancer choice in sync across your devices, and lets OnCo alert you when a trial or treatment you follow changes. No password: we email you a sign-in link.

Account creation is being switched on. Until then, press Watch on any page and your list stays in this browser.

Cancers & treatments·Sequencing

PDGFRA D842V-mutant GIST: lines of therapy

Cancer page →

3 standard-of-care settings across 3 lines and 1 biomarker subgroup. Rows come from the cancer page's standard of care; the grid places each on its line and subgroup.

LineAll comers
Early / localised1
Advanced, first line1
Second line1

Early / localised

SubgroupSettingApproachProducts and trialsEvidence
All comersLocalised, resectableSurgical resection; no adjuvant imatinib because the mutation is resistant to it.
Robotic & minimally invasive surgeryPDGFRA
54

Advanced, first line

SubgroupSettingApproachProducts and trialsEvidence
All comersAdvanced, first lineAvapritinib 300 mg daily (NAVIGATOR), with monitoring for cognitive effects and bleeding.
AvapritinibPDGFRAKIT
66

Second line

SubgroupSettingApproachProducts and trialsEvidence
All comersProgression on avapritinibNo established therapy; clinical trials, surgery or embolisation for isolated progression; regorafenib and other kinase inhibitors have low activity.
RegorafenibVOYAGERLiquid biopsy (ctDNA)
87

Lines and subgroups are parsed from the setting text of each standard-of-care row and can misclassify an unusual phrasing; the row’s own setting is always shown. Guideline chips reflect the NCCN category and ESMO-MCBS grade recorded on the cancer page, checked on its stated date. Not medical advice.